Search Results 1081-1090 of 17599 for Assay

  1. Medical Laboratory Science Program (Florida and Minnesota)

    Professional skills. Perform a wide variety of laboratory tests from low to high complexity; Troubleshoot laboratory assays, identifying and correcting ...

  2. A pivotal study of derazantinib in patients with inoperable or advanced intrahepatic cholangiocarcinoma and FGFR2 gene fusions or FGFR2 gene mutations or amplifications - Mayo Clinic

    For enrollment of patients in the EU, assays must be fully CE-marked. ** The patient must not be enrolled if a negative FISH test is obtained from the ...

  3. Nemvaleukin Alfa (ALKS 4230) Monotherapy in Patients With Advanced Cutaneous Melanoma or Advanced Mucosal Melanoma - Mayo Clinic

    Cohort 4 - Patients are required to have known tumor PD-\[L\]1 status determined by local testing using an approved assay. PD-\[L\]1 testing performed prior ...

  4. Biomarker-guided CNI substitution in Kidney Transplantation Assessment - Mayo Clinic

    T-SPOT-TB assay OR has completed treatment for latent tuberculosis and has a negative chest x-ray. PPD or IGRA testing must occur within 52 weeks prior to ...

  5. Publications - Ray Guo, M.D., Ph.D. - Mayo Clinic

    SARCP, a Clinical Next-Generation Sequencing Assay for the Detection of Gene Fusions in Sarcomas: A Description of the First 652 Cases. J Mol Diagn. 2025 ...

  6. A Study of Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis (DT/AF) - Mayo Clinic

    About this study. The NIR-DT-301 Phase 3, double-blind, placebo-controlled study is being conducted to determine the efficacy, safety, and tolerability of ...

  7. Evaluation of Laboratory Methods for Detecting Auto Antibodies to Complement Proteins - Mayo Clinic

    The goal of this study is to validate testing to be performed in the clinical immunology lab and have a source of positive patient sera. These tests include:.

  8. I-124 evuzamitide PET/CT Imaging for the Diagnosis of Cardiac Amyloidosis - Mayo Clinic

    Inclusion Criteria: Understands the study procedures and can give signed informed consent (as specified in Section 10.1.3), which includes compliance with ...

  9. Phase II Single-arm Study of Tepotinib Combined with Cetuximab - Mayo Clinic

    ... assay; AND a barrier method,; During the intervention period;; After the study intervention period (i.e., after the last dose of study intervention is ...

  10. S1400 Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer - Mayo Clinic

    ... assays in clinical practice, 2) have cluster of differentiation (CD)4 count >= 400/mcL, 3) not require prophylaxis for any opportunistic infections (i.e. ...